PT - JOURNAL ARTICLE AU - Leung, Kathy AU - Pei, Yao AU - Leung, Gabriel M AU - Lam, Tommy TY AU - Wu, Joseph T TI - Empirical transmission advantage of the D614G mutant strain of SARS-CoV-2 AID - 10.1101/2020.09.22.20199810 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.22.20199810 4099 - http://medrxiv.org/content/early/2020/09/23/2020.09.22.20199810.short 4100 - http://medrxiv.org/content/early/2020/09/23/2020.09.22.20199810.full AB - The SARS-CoV-2 lineage carrying the amino acid change D614G has become the dominant variant in the global COVID-19 pandemic. The rapid spread of the G614 mutant suggests that it may have a transmission advantage over the D614 wildtype. Using our previous epidemiological framework to analyze COVID-19 surveillance and sequence data, we estimated that the G614 mutant is 31% (28-34%) more transmissible than the D614 wildtype. As such, interventions that were previously effective in containing or mitigating the D614 wildtype (e.g. in China, Vietnam, Thailand, etc.) might be less effective against the G614 mutant. Our framework can be readily integrated into current COVID-19 surveillance to monitor the emergence and fitness of mutant strains, such that pandemic surveillance, disease control and development of treatment and vaccines can be adjusted dynamically.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by a commissioned grant from the Health and Medical Research Fund from the Government of the Hong Kong Special Administrative Region, and the National Natural Science Foundation of China (NSFC) Excellent Young Scientists Fund (Hong Kong and Macau) (grant no.: 31922087). The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish. All authors have seen and approved the manuscript. All authors have contributed significantly to the work. All authors report no conflicts of interest. The manuscript and the data contained within have not been published and are not being considered for publication elsewhere.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval is exempted because the study only use sequence data that are publicly available on GISAID.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collated all data from publicly available data sources. All the information that we used is available in the main text or the supplementary materials.